Revenue and Sales Performance - Revenue from the core product "Kang En Bei" brand Changyanning series reached 1.1 billion yuan, driven by increased brand promotion and marketing efforts[8] - Sales of "Kang En Bei" brand health food exceeded 400 million yuan, maintaining rapid growth through new product categories and channel expansion[8] - "Jin Kang Su Li" brand acetylcysteine effervescent tablets saw a 36% year-on-year sales increase[8] - Revenue for the first three quarters of 2023 reached 5.184 billion yuan, a year-on-year increase of 15.51%[33] - The traditional Chinese medicine and health products business generated revenue of 3.442 billion yuan in the first three quarters of 2023, accounting for 66.40% of total revenue, an increase of 4.29 percentage points year-on-year[34] - Self-care products business revenue reached 2.34 billion yuan in the first three quarters of 2023, a year-on-year increase of 23.68%[34] - Total revenue for the first three quarters of 2023 reached 5,184,266,884.99 RMB, a 15.5% increase compared to 4,488,268,722.41 RMB in the same period of 2022[48] - Revenue for the first three quarters of 2023 was 467,209,320.47, slightly down from 468,543,746.86 in the same period of 2022[72] Profit and Earnings - Net profit attributable to shareholders in Q3 2023 was 107.11 million yuan, a 532.29% increase year-on-year[14] - Net profit attributable to shareholders for the first nine months of 2023 was 623.24 million yuan, a 171.76% increase year-on-year[14] - Basic earnings per share for the first nine months of 2023 were 0.243 yuan, a 173.03% increase year-on-year[13] - Net profit attributable to shareholders of the listed company for the first three quarters of 2023 was 623.24 million yuan, a year-on-year increase of 171.76%[33] - Net profit attributable to parent company shareholders in the first three quarters of 2023 was 623,237,394.18 RMB, a 171.8% increase from 229,330,778.30 RMB in the same period of 2022[50] - Basic earnings per share for the first three quarters of 2023 were 0.243 RMB, a 173.0% increase from 0.089 RMB in the same period of 2022[50] - Net profit for the first three quarters of 2023 reached 974,847,499.92 RMB, a significant increase from 254,063,617.36 RMB in the same period of 2022[58] - Total comprehensive income for the first three quarters of 2023 was 699,887,141.20 RMB, a 130.1% increase from 304,164,855.70 RMB in the same period of 2022[50] - Total comprehensive income for the first three quarters of 2023 was 974,847,499.92 RMB, compared to 254,063,617.36 RMB in the same period of 2022[58] Financial Position and Assets - The company's total assets as of the end of Q3 2023 were 11.16 billion yuan, a 2.12% increase compared to the end of the previous year[13] - Total assets as of September 30, 2023, were 11,161,783,747.52 RMB, a 2.1% increase from 10,929,964,949.51 RMB as of December 31, 2022[48] - Total assets as of September 30, 2023: 11,161,783,747.52 RMB, an increase from 10,929,964,949.51 RMB at the end of 2022[46] - Total assets increased to 9,149,583,925.25 RMB as of September 30, 2023, compared to 8,248,072,073.79 RMB at the end of 2022[56] - Total assets increased to 9,149,583,925.25 as of September 30, 2023, compared to 8,248,072,073.79 at the end of 2022[69] Liabilities and Debt - The company issued 200 million yuan in short-term financing bonds with an annualized interest rate of 2.26% and a 180-day maturity[24] - Short-term borrowings decreased by 71.14%, mainly due to the repayment of maturing debts and optimization of the debt structure[38] - The company issued 400 million yuan in ultra-short-term financing bonds, leading to a 3035.32% increase in other current liabilities[38] - Short-term borrowings as of September 30, 2023: 207,156,833.35 RMB, a significant decrease from 717,733,669.45 RMB at the end of 2022[47] - The company issued 200 million RMB in ultra-short-term financing bonds on April 12, 2023, with an annualized interest rate of 2.75% and a maturity of 180 days[43] - The company completed the repayment of the 2023 first ultra-short-term financing bonds on October 9, 2023, with a total principal and interest repayment of 202,704,918.03 RMB[43] - Total liabilities as of September 30, 2023, were 3,643,808,920.61 RMB, a slight increase from 3,605,940,336.82 RMB as of December 31, 2022[48] - Total liabilities increased to 2,260,971,655.15 RMB as of September 30, 2023, compared to 1,948,801,705.76 RMB at the end of 2022[56] - Short-term borrowings decreased to 100,078,527.80 from 590,614,472.22 at the end of 2022[69] - Other payables increased to 1,673,078,520.20 from 1,160,639,969.00 at the end of 2022[69] Cash Flow and Liquidity - Operating cash flow for the first three quarters of 2023 was 658,417,306.12 RMB, a 26.8% increase compared to 519,268,865.96 RMB in the same period of 2022[52] - Cash received from sales of goods and services in the first three quarters of 2023 was 4,918,985,676.09 RMB, a 20.9% increase compared to 4,066,906,508.23 RMB in the same period of 2022[52] - Investment cash outflow in the first three quarters of 2023 was 586,381,700.11 RMB, a 60.7% increase compared to 364,826,903.99 RMB in the same period of 2022[52] - Cash and cash equivalents at the end of September 2023 stood at 2,140,028,244.30 RMB, compared to 1,844,641,962.75 RMB at the end of September 2022[68] - Net cash flow from financing activities was -758,822,252.32 RMB for the first three quarters of 2023, an improvement from -826,474,430.45 RMB in the same period of 2022[68] - Cash flow from operating activities was -22,699,668.75 for the first three quarters of 2023, an improvement from -28,629,512.01 in the same period of 2022[75] - Cash flow from investing activities was 490,609,179.32, significantly higher than 66,623,305.34 in the same period of 2022[75] - Cash flow from financing activities was -80,240,698.71, compared to -71,126,848.45 in the same period of 2022[75] - Net increase in cash and cash equivalents was 387,840,691.54, a significant improvement from -32,400,347.80 in the same period of 2022[75] Equity and Shareholder Information - Total number of ordinary shareholders at the end of the reporting period: 105,122[40] - Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. holds 535,777,040 shares, representing 20.85% of total shares[40] - Kanghong Group Co., Ltd. holds 223,431,171 shares, representing 8.69% of total shares[40] - Hu Jiqiang holds 133,579,085 shares, representing 5.20% of total shares, with 51,000,000 shares pledged[40] - Total equity attributable to parent company shareholders as of September 30, 2023, was 7,124,709,758.65 RMB, a 3.0% increase from 6,913,851,405.56 RMB as of December 31, 2022[48] - Total owner's equity (or shareholders' equity) rose to 6,888,612,270.10 RMB as of September 30, 2023, up from 6,299,270,368.03 RMB at the end of 2022[56] - Undistributed profits rose to 2,069,596,367.73 RMB as of September 30, 2023, up from 1,500,788,890.46 RMB at the end of 2022[56] Investments and Financial Instruments - The company transferred 7.84% equity of Jiangxi Zhenshiming Pharmaceutical Co., Ltd., resulting in a net profit of 86.72 million yuan[36] - Non-recurring gains and losses from the disposal of non-current assets amounted to 71.27 million yuan, mainly due to the transfer of equity in Zhenshiming Company[36] - The fair value change loss of financial assets was 66.86 million yuan, mainly due to the decline in the market value of Genor Biopharma shares[36] - Long-term equity investments grew to 6,071,498,745.82, up from 5,609,019,375.18 at the end of 2022[69] - Investment income surged to 1,014,996,916.07 in the first three quarters of 2023, compared to 265,554,181.02 in the same period of 2022[72] Expenses and Impairments - R&D expenses and equity incentive costs increased by approximately 30 million yuan year-on-year, impacting net profit[14] - Credit impairment losses for the first three quarters of 2023 were 1,871,858.83 RMB, down from 12,212,182.73 RMB in the same period of 2022[58] Other Financial Metrics - The company's weighted average return on equity for the first nine months of 2023 was 8.81%, an increase of 5.61 percentage points year-on-year[13] - Accounts receivable increased by 51.26%, mainly due to the growth in sales revenue[38] - Accounts receivable as of September 30, 2023: 1,441,951,041.98 RMB, an increase from 953,307,487.57 RMB at the end of 2022[46] - Monetary funds as of September 30, 2023: 2,244,231,034.18 RMB, a decrease from 2,468,031,909.97 RMB at the end of 2022[46] - Deferred income decreased to 2,936,700.00 RMB as of September 30, 2023, from 4,142,400.00 RMB at the end of 2022[56]

浙江康恩贝制药股份有限公司 环境、社会责任及公司治理（ESG） 信息披露管理办法 第一章 总 则 第一条 为构建科学、系统、规范的环境、社会责任及公司 治理（Environment, Social and Governance，以下简称：ESG） 工作体系，加强浙江康恩贝制药股份有限公司（以下简称：公 司）ESG 信息披露管理，强化公司 ESG 自我约束机制，推动公 司实现可持续高质量发展，根据财政部、证监会等有关部门的 《企业内部控制应用指引第 4 号-社会责任》、中国证监会《上 市公司治理准则》，国家生态环境部《企业环境信息依法披露 管理办法》、上海证券交易所《上市公司环境信息披露指引》、 上海证券交易所《上市公司自律监管指引第 2 号——信息披露 事务管理》，以及《浙江康恩贝制药股份有限公司信息披露事 务管理制度》等的相关规定，制定本办法。 第二条 本办法适用于公司 ESG 信息编制、披露事务的管 理。 （四）完整性：应披露对利益相关方做出价值判断和决策 有重大影响的所有信息，信息内容完整、全面具体。 （五）一致性：使用一致的披露统计方法，使披露的信息 能为利益相关方进行有意义的比较。 第五条 本办法未 ...

浙江康恩贝制药股份有限公司(以下简称：公司)十届董事会第三十四次（临时）会 议于 2023 年 10 月 27 日以通讯方式召开。会议通知于 2023 年 10 月 25 日以书面、传真、 电子邮件方式送达各董事。会议应参加审议表决董事 11 人，实际参加审议表决董事 11 人。公司监事以审议有关议案方式列席会议。会议的召开符合《公司法》、《公司章程》 的规定。 会议审议了以下议案，经书面表决通过决议如下： 证券代码：600572 证券简称：康恩贝 公告编号：临 2023-065 浙江康恩贝制药股份有限公司 十届董事会第三十四次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 2023 年 10 月 28 日 1 一、审议通过《公司 2023 年第三季度报告》。表决情况：同意 11 票，反对 0 票， 弃权 0 票。（2023 年第三季度报告详见上海证券交易所网站：http://www.sse.com.cn）。 二、审议通过《关于制定<浙江康恩贝制药股份有限公司环境、社会责任及公司治 理（ESG）信息披露管 ...

浙江康恩贝制药股份有限公司董事、监事和高级管理人员 对公司 2023 年第三季度报告的书面确认意见 根据《证券法》及《上市公司信息披露管理办法》的相关要求,我们作为公司董 事、监事和高级管理人员在全面了解和审核公司 2023年第三季度报告后,认为:公 司严格按照股份制公司财务制度规范运作,公司 2023 年第三季度报告公允地反映了 公司本季度的财务状况和经营成果,是实事求是、客观公正的;我们保证公司 2023 年第三季度报告所披露的信息真实、准确、完整,承诺其中不存在虚假记载、误导性 陈述或重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 董事签名: | | | --- | --- | | 胡季强 | 应春晓 | | 罗国良 | 程兴华 | | 江 洋 | 谋 明 | | 袁振贤 | 吕久琴 | | 董作军 | 吴永江 | | 刘 恩 | | | 监事签名: | | | 尹石水 | 吴仲时 | | 叶剑锋 | | 浙江康恩贝制药股份有限公司董事、监事和高级管理人员 对公司 2023 年第三季度报告的书面确认意见 根据《证券法》及《上市公司信息披露管理办法》的相关要求,我们作为公司董 事、监 ...

证券代码：600572 证券简称：康恩贝 公告编号：临 2023-064 浙江康恩贝制药股份有限公司 关于向激励对象授予2022年股票期权激励计划 预留股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江康恩贝制药股份有限公司（以下简称：公司、本公司）于 2023 年 10 月 25 日召开十届董事会第三十三次（临时）会议和十届监事会第二十次（临时）会议， 审议通过《关于向激励对象授予 2022 年股票期权激励计划预留股票期权的议案》。 根据公司 2022 年股票期权激励计划（以下简称：本次激励计划）的相关规定和公司 2022 年第二次临时股东大会有关决议的授权，公司董事会、监事会均认为公司本次 激励计划规定的预留股票期权授予条件已经成就，确定以 2023 年 10 月 25 日为本次 激励计划预留股票期权授予日，向符合条件的 103 名激励对象授予 752.5 万份预留 股票期权。现将相关事项公告如下： 一、股票期权授予情况 （一）本次激励计划已履行的决策程序和信息披露情况 1、2022 年 ...

| 内 容 | 《关于向激励对象授予 2022年股票期权激励计划预留股票期权的议案》议案 | | --- | --- | | 目 意 | 1. 根据公司 2022年第一次临时股东大会的授权,董事会确定 2022年股票期权额加计划 预留股票期权授予目为2023年10月25日,该授予目符合中国证监会《上市公司股权激励管 理办法》及《浙江康恩贝制药股份有限公司 2022年股票期权激励计划(草案)》中关于授予 目的相关规定,同时本次授予也符合本次激励对象获授预留股票期权条件的相关规定。 | | | 2、公司不存在《上市公司股权激励管理办法》等法律、法规和规范性文件规定的禁止实 施本次股权激励计划的情形,公司具备实施本次股权激励计划的主体资格。 3、本次拟授予预留股票期权的激励对象不存在禁止获授股票期权的情形,激励对象的主 | | | 体资格合法、有效,激励对象范围的确定符合公司实际情况以及公司业务发展的实际需要。 4、公司和潮励对象均未发生不得授予股票期权的情形,公司本次股票期权激励计划规定 的预留股票期权授予条件已成就。 | | | 5、公司实施股权激励计划有利于进一步建立、健全公司长效激励机制,吸引和留在优秀 人 ...

上海东方华银律师事务所 关于浙江康恩贝制药股份有限公司 2022 年股票期权激励计划授予事项 之 法律意见书 上海东方华银律师事务所 上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 电话：(8621) 68769686 上海东方华银律师事务所 关于浙江康恩贝制药股份有限公司 2022 年股票期权激励计划授予事项之法律意见书 致：浙江康恩贝制药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会（以下 简称"中国证监会"）发布的《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《国有控股上市公司（境内）实施股权激励试行办法》等有关法 律、法规、规章、规范性文件的规定和《浙江康恩贝制药股份有限公司章程》（以 下简称"《公司章程》"），上海东方华银律师事务所（以下简称"本所"）接 受浙江康恩贝制药股份有限公司（以下简称"康恩贝"或"公司"）的委托，就 公司 2022 年股票期权激励计划（以下简称"本激励计划"）预留股票期权授予 相关事项出具本法律意见书。 为出具本法律意见书，本所律师特作以下声明： 本所律师已严 ...

激励对象 获授的股票期权 数量(万份) 占股票期权激励 计划总量的比例 占授予时公司 股本总额的比 例 公司及下属公司管理人员、核心骨 干【103】人 752.5 10.75% 0.2928% 二、2022 年股票期权激励计划预留股票期权授予激励对象名单 | 22 | 吴红 | 下属子公司其他管理人员、核心骨干 | | --- | --- | --- | | 23 | 陈娇 | 下属子公司其他管理人员、核心骨干 | | 24 | 华洁 | 下属子公司其他管理人员、核心骨干 | | 25 | 杨晓楠 | 下属子公司其他管理人员、核心骨干 | | 26 | 高屹嵩 | 下属子公司其他管理人员、核心骨干 | | 27 | 沈志元 | 下属子公司其他管理人员、核心骨干 | | 28 | 郑烨 | 下属子公司其他管理人员、核心骨干 | | 29 | 张晓谦 | 下属子公司其他管理人员、核心骨干 | | 30 | 刘彩霞 | 下属子公司其他管理人员、核心骨干 | | 31 | 张艳 | 下属子公司其他管理人员、核心骨干 | | 32 | 赵爱荣 | 下属子公司其他管理人员、核心骨干 | | 33 | 王晓光 | 下属子公 ...

证券代码：600572 证券简称：康恩贝 公告编号：临 2023-063 浙江康恩贝制药股份有限公司 股权事项完成工商变更登记备案的公告 董 事 会 2023 年 10 月 21 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 鉴于浙江康恩贝制药股份有限公司（以下简称：公司）全资子公司浙江金华康 恩贝生物制药有限公司（以下简称：金华康恩贝）自2016年以来对浙江耐司康药业 有限公司（以下简称：耐司康药业）进行托管经营，耐司康药业目前基本具备可持 续经营和盈利能力，为有利于金华康恩贝整体布局和专业化、规模化发展，进一步 打造充实公司化学药事业部平台，经公司于2023年10月16日召开的十届董事会第三 十二次（临时）会议审议通过，同意金华康恩贝以人民币18,322.75万元受让公司关 联方杭州康盟投资合伙企业（有限合伙）持有的耐司康药业80.58%股权（按《耐司 康药业公司章程》约定，该等股权实际对应56.74%的股东权利）。（具体内容详见 2023年10月18日公司在《中国证券报》、《上海证券报》、《证券时报》及上海证券交 ...

浙江康恩贝制药股份有限公司 十届董事会第三十二次(临时)会议 独立董事签名: B / / /11 独立董事意见表 | 内 | 容 | 关于公司子公司金华康恩贝受让康盟投资所持耐司康药业股权的 | | | --- | --- | --- | --- | | 议案 | | | | | 本次公司全资子公司浙江金华康恩贝生物制药有限公司(简称:金华康 | 恩贝)受让关联方所持浙江耐司康药业有限公司(简称:耐司康药业)股权, | | | | 有利于充分整合金华康恩贝与耐司康药业资源,加快公司特色化学药事业部 | 可 | 意 | 平台建设,符合本公司及金华康恩贝的长远规划及发展战略,我们同意本次 | | 股权受让关联交易事项。 | | | | | 本次关联交易的评估机构具有独立性;评估假设前提具有合理性;评估 | 结果客观、公正地反映了评估基准日评估对象的实际情况,评估定价公允。 | | | | 本次关联交易表决程序符合相关法律、法规和公司章程规定,相关的关联董 | 事按规定回避表决,交易价格符合公允、合理的市场原则,本项关联交易不 | | | | 会损害公司及公司股东利益。 | | | | | 保留意见 | | | | ...